Abstract

Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease

Author(s): Corsini Lindsay, Williams LaVonn A

Issue: Mar/Apr 2011 - Volume 15, Number 2

Page(s): 124-128

Download in electronic PDF format for $75

Abstract

In the pediatric patient, histamine2-receptor antagonists and/or proton pump inhibitors are recommended for effective therapy of gastroesophageal reflux disease. Proton pump inhibitors, a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production, are more cost effective than histamine2-receptor antagonists because of long-term and enhanced treatment outcome. The compounding of proton pump inhibitors is an exacting procedure. Compounding pharmacists have the potential to provide optimal pharmacologic treatment of gastroesophageal reflux disease to a young population that requires special attention.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Mar/Apr 2011 Pg. 124-128	Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Author(s): Corsini Lindsay, Williams LaVonn A
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
Jan/Feb 2019 Pg. 58	Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 504-510	Compatibility of Flavoring Agents in Compounding Extemporaneous Omeprazole Oral Liquid Author(s): Chuong Monica, Taglieri Catherine A, Huang Szu Yu, Sariol Anthony, Kitigawa Reina, Barman Koushik, Mistry Amee, Harris Donna L, Kerr Stephen G
May/Jun 2010 Pg. 246	Lansoprazole 3-mg/mL Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 140-147	The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Author(s): Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
May/Jun 2023 Pg. 250-255	Stability of Omeprazole Extemporaneous Oral Solution in Chopin Base Author(s): Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
Sep/Oct 2006 Pg. 391	Pantoprazole Sodium 2-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Jan/Feb 2001 Pg. 6-8	Pediatric Compounding: Coloring Outside the Lines Author(s): Preckshot John
Sep/Oct 2006 Pg. 389	Omeprazole 2-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Nov/Dec 2017 Pg. 500-512	To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid Author(s): Chuong Monica C, Taglieri Catherine A, Kerr Stephen G
May/Jun 2003 Pg. 188-191	Treating Canine Hepatic Disease Author(s): Davidson Gigi S
Jan/Feb 2007 Pg. 74	Lansoprazole 3-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Nov/Dec 2005 Pg. 423-431	Compounding for a Pediatric Hospital Author(s): McElhiney Linda F
Sep/Oct 2022 Pg. 429	Lansoprazole 3-mg/mL in Ora-Blend Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2022 Pg. 293-296	Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases Author(s): Harrington Amy, Williams LaVonn
Jan/Feb 2001 Pg. 9-12	Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients Author(s): Schotik Debora
May/Jun 2016 Pg. 247-249	Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children Author(s): Nahata Milap C
Mar/Apr 2012 Pg. 164-166	Stability of Omeprazole in SyrSpend SF Alka (Reconstituted) Author(s): Whaley Paul A, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2015 Pg. 521-524	Long-term Stability of Esomeprazole in 5% Dextrose Infusion Polyolefin Bags at 5°C ± 3°C after Microwave Freeze-thaw Treatment Author(s): Hecq Jean-Daniel, Rolin Catherine, Godet Marie, Gillet Patricia, Jamart Jacques, Galanti Laurence M